Genetic alterations and their therapeutic implications in epithelial ovarian cancer.

ABSTRACT:

Background

Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alteration patterns of individual patients.

Methods

We sequenced 410 genes to analyze mutations and CNV of 82 ovarian carcinomas, including high-grade serous (n = 37), endometrioid (n = 22) and clear cell (n = 23) histologies. Eligibility for targeted therapy was determined for each patient by a pathway-based approach. The analysis covered DNA repair, receptor tyrosine kinase, PI3K/AKT/MTOR, RAS/MAPK, cell cycle, and hedgehog pathways, and included 14 drug targets.

Results

Postulated PARP, MTOR, and CDK4/6 inhibition sensitivity were m

SUBMITTER: Lapke N 

PROVIDER: S-EPMC8097933 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature